Precede Biosciences closed roughly $83.5–$84 million in financing (Series B plus a $20 million credit facility) to scale its liquid biopsy platform and expand partnerships with pharma. The Boston company uses RNA‑based, genome‑wide expression readouts from blood to profile tumor biology and support drug development, citing existing collaborations across ~30 clinical programs. CEO Rehan Verjee said the funding will expand capacity and commercial engagement with oncology developers, especially for ADCs and radiopharmaceutical programs. The round included strategic investors such as Labcorp Venture Fund, UPMC Enterprises and Bristol Myers Squibb. For readers in diagnostics and drug development, the deal underscores rising demand for advanced circulating biomarkers to guide patient selection and mechanism‑of‑response workstreams.